Shares in Small-Cap Star Idera Pharmaceuticals (IDRA) are up today following the announcement of an agreement with Abbott Laboratories (ABT) to develop a companion diagnostics test for use in clinical ...

CAMBRIDGE, Mass. and EXTON, Pa, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer and sell up to $60 ...

Small-Cap Star Idera Pharmaceuticals (IDRA) popped on Thursday, climbing almost 11 percent on extremely heavy volume. Shares opened close to even, starting up 1.1 percent to $2.75 a share. However, ...

EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (IDRA) (“Idera,” the “Company,” “we,” “us,” or “our ...

Stock in Idera Pharmaceuticals tanked this week when Celgene announced that the FDA approved Otezla (apremilast) for psoriatic arthritis, a major competitor of Idera's Phase II candidate, IMO-8400.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The purchase of 5.3 million shares for $3.75 each by ...

LONDON (MarketWatch) -- Idera Pharmaceuticals Inc. said that it has appointed Robert Karr, as president. Karr has served on the company's board since June of this year and will continue in this role.

* Idera Pharmaceuticals Inc - ‍intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering * Idera - intends to use net proceeds from offering, ...